Biogen Reports Five-Year CHERISH Data for Spinraza in Later-Onset SMA

Biogen today presented five-year follow-up data from the Phase 3 CHERISH trial evaluating Spinraza (nusinersen) in patients with later-onset spinal muscular atrophy. The data showed that Spinraza maintained significant improvements in motor function over five years of treatment, with patients who received Spinraza showing better outcomes than those who received sham procedure.